Atai Beckley N.V. (DE:B72)
FRANKFURT:B72
B72 Stock Chart & Stats
€3.22
-€0.07(-3.75%)
At close: 4:00 PM EST
€3.22
-€0.07(-3.75%)
Day’s Range― - ―
52-Week Range€1.17 - €6.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.35K
Market Cap
€1.17B
Enterprise Value€642.98M
Total Cash (Recent Filing)€256.04M
Total Debt (Recent Filing)€2.07M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding364,745,970
10 Day Avg. Volume2,169
30 Day Avg. Volume2,346
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.99Price Target Upside272.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.4
Revenue Forecast (FY)€395.80K
Bulls Say, Bears Say
Bulls Say
Regulatory & Clinical ProgressPeer-reviewed Phase 2a efficacy with FDA Breakthrough designation and End-of-Phase-2 alignment materially raises the program's regulatory probability of success. This structurally accelerates development timelines, improves partner interest, and de-risks a lead asset over the 2–6 month horizon.
Proprietary, Patent-Protected FormulationPatent protection and a differentiated intranasal delivery create product-level IP and clinical differentiation. A single-dose, short-duration outpatient profile supports adoption, reimbursement discussions, and a defensible commercial position versus competitors over the medium term.
Balance Sheet: Low LeverageLow debt and a sizable equity/assets cushion provide financial flexibility to fund clinical programs and pursue partnerships without immediate solvency pressure. This reduces short-term refinancing risk and supports execution through upcoming Phase 3 milestones.
Bears Say
Consistent Heavy Cash BurnSustained negative operating and free cash flow creates ongoing funding dependence. Unless burn meaningfully moderates or external financing/partnerships are secured, the company may need dilutive raises that impair shareholder value and constrain long-term strategic optionality.
Large, Volatile Net LossesA massive one-year net loss signals significant write-offs, non-cash charges, or concentrated R&D spend that dilute equity and depress returns. Persistent earnings volatility complicates planning and heightens the need for external capital or partner monetization of assets.
Minimal And Volatile Revenue BaseRevenue remains tiny relative to development costs and is volatile, underscoring an unproven commercial model. The company remains early-stage, reliant on clinical milestones rather than product sales, which limits near-term self-funding and increases execution risk.
Atai Beckley N.V. News
B72 FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was €1.17 and its highest was €6.00 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is €1.17B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is May 20, 2026 which is in 35 days.
How were Atai Beckley N.V.’s earnings last quarter?
Currently, no data Available
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. does not currently pay dividends.
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 364,745,970 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in DE:B72
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Company Description
Atai Beckley N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
B72 Stock 12 Month Forecast
Average Price Target
€11.99
▲(272.35% Upside)
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Options Prices
Currently, No data available
---